Original Source(s)
Related Content
Oral Aleniglipron Reduced Weight at 36 Weeks
In a phase 2b trial, the highest dose produced an estimated 12% mean weight reduction vs 1% with placebo, although gastrointestinal adverse events were common.
July 16, 2026
-
6 min
Medical Oddities: Natural Doesn't Always Mean Safe
From the gym to the kitchen to romance, these studies challenge everyday assumptions.
by Teraya Smith
July 15, 2026
-
4 min
FDA Approves First Oral PCSK9 Inhibitor
Merck reported placebo-adjusted LDL-C reductions of 56% and 59% at week 24 in two phase 3 CORALreef trials supporting the approval.
July 16, 2026
-
2 min